TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Comparison of Intravenous Versus Oral Administration of Prednisolone in the Treatment of Exacerbations of Chronic Obstructive Pulmonary Disease
Brief Summary: Treatment with systemic corticosteroids for acute exacerbations of COPD results in the improvement of clinical outcomes. The optimal route of administration has not been rigorously studied in COPD. Upon hospitalization, corticosteroids are administered intravenously in many hospitals. Oral administration is more convenient, though, because there is no need for intravenous access, less personnel is required for starting and monitoring therapy, and material costs are smaller.

The investigators hypothesized that oral administration is not inferior to intravenous administration of prednisolone in the treatment of patients hospitalized for an acute exacerbation of COPD.


Options:
A: Arm Label: Aclidinium bromide 200 μg bid; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide 200 μg bid | Arm Label: Aclidininum bromide 400 μg bid; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide 400 μg bid | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium bromide 200 μg bid; Assigned to Arm(s): Aclidinium bromide 200 μg bid | Intervention Type: DRUG; Name: Aclidinium bromide 400 μg bid; Assigned to Arm(s): Aclidininum bromide 400 μg bid | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: AZD9668 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: AZD9668 | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: AZD9668 | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: AZD9668 Placebo | Intervention Type: DRUG; Name: AZD9668; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: AZD9668; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: AZD9668; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: AZD9668 Placebo; Assigned to Arm(s): 4
C: Intervention Type: DRUG; Name: Intravenous prednisolone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Oral prednisolone; Assigned to Arm(s): N/A
D: Arm Label: COPD subjects; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Non-smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Intervention Type: OTHER; Name: Novel endpoint determination; Assigned to Arm(s): COPD subjects, Non-smoker controls, Smoker controls

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Feasibility and Impact of Qigong as Compared to Aerobic Exercise in the Treatment of Childhood Chronic Musculoskeletal Pain: A Pilot Randomized Controlled Trial.
Brief Summary: This study is comparing two different exercise programs, Qi Gong (gentle stretching, and breathing) with an aerobics program (boxing and dancing) to see if children with chronic pain or fibromyalgia are able to take part in the program. We would also like to know if it is easy to take part in an exercise program.

We hypothesize that children with chronic musculoskeletal pain and FM, who engage in Qigong fitness training, will be more compliant, and have an equivalent or possibly superior improvement on measures of motor function (peak power, endurance, and metabolic efficiency) compared to children given an aerobic fitness exercise program.


Options:
A: Arm Label: Education Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Education | Arm Label: Pain Self-Management Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Pain self-management, Behavioral: Education | Intervention Type: BEHAVIORAL; Name: Pain self-management; Assigned to Arm(s): Pain Self-Management Intervention | Intervention Type: BEHAVIORAL; Name: Education; Assigned to Arm(s): Education Control, Pain Self-Management Intervention
B: Intervention Type: BEHAVIORAL; Name: Aerobic and Qi gong Exercise; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: Aerobic exercise; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Qigong exercise; Assigned to Arm(s): N/A
D: Arm Label: Internet-based JIA Self-Management Program; Type: EXPERIMENTAL; Interventions: Behavioral: Teens Taking Charge | Arm Label: Attention Control Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Self-Management | Intervention Type: BEHAVIORAL; Name: Teens Taking Charge; Assigned to Arm(s): Internet-based JIA Self-Management Program | Intervention Type: BEHAVIORAL; Name: Self-Management; Assigned to Arm(s): Attention Control Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open, Randomized, Multicenter Study of the Safety, Tolerability, & Immunogenicity of VAQTA™ Given Concomitantly With PROQUAD™ and PREVNAR™ in Healthy Children 12 Months of Age
Brief Summary: Hepatitis A vaccine will be given either alone or together with measles, mumps, rubella, and varicella vaccine and pneumococcal 7-valent conjugate vaccine at the first dose and together with measles, mumps, rubella, and varicella \[Oka/Merck\] virus vaccine at the second dose. Immunogenicity and safety data will be collected after each dose of vaccine.


Options:
A: Intervention Type: BIOLOGICAL; Name: 10 valent pneumococcal conjugate (vaccine); Assigned to Arm(s): N/A
B: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Biological: Priorix-Tetra™ (MMRV vaccine 208136), Biological: Havrix®, Biological: Prevnar® | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Biological: Priorix-Tetra™ (MMRV vaccine 208136), Biological: Havrix®, Biological: Prevnar® | Arm Label: Group C; Type: ACTIVE_COMPARATOR; Interventions: Biological: ProQuad®, Biological: Havrix®, Biological: Prevnar® | Intervention Type: BIOLOGICAL; Name: Priorix-Tetra™ (MMRV vaccine 208136); Assigned to Arm(s): Group A, Group B | Intervention Type: BIOLOGICAL; Name: ProQuad®; Assigned to Arm(s): Group C | Intervention Type: BIOLOGICAL; Name: Havrix®; Assigned to Arm(s): Group A, Group B, Group C | Intervention Type: BIOLOGICAL; Name: Prevnar®; Assigned to Arm(s): Group A, Group B, Group C
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: Comparator: VAQTA™ (Hepatitis A vaccine), Biological: Comparator: ProQuad™ (Measles, Mumps, Rubella and Varicella vaccine), Biological: Comparator: Prevnar™ (Pneumococcal 7-Valent Conjugate vaccine) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: Comparator: VAQTA™ (Hepatitis A vaccine), Biological: Comparator: ProQuad™ (Measles, Mumps, Rubella and Varicella vaccine), Biological: Comparator: Prevnar™ (Pneumococcal 7-Valent Conjugate vaccine) | Intervention Type: BIOLOGICAL; Name: Comparator: VAQTA™ (Hepatitis A vaccine); Assigned to Arm(s): 1, 2 | Intervention Type: BIOLOGICAL; Name: Comparator: ProQuad™ (Measles, Mumps, Rubella and Varicella vaccine); Assigned to Arm(s): 1, 2 | Intervention Type: BIOLOGICAL; Name: Comparator: Prevnar™ (Pneumococcal 7-Valent Conjugate vaccine); Assigned to Arm(s): 1, 2
D: Intervention Type: BIOLOGICAL; Name: M-M-R™II manufactured with recombinant Human Albumin (rHA) and VARIVAX®; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Neuroscience-Guided Remediation of Cognitive Deficits in Schizophrenia
Brief Summary: This study will determine the effectiveness of reward-intensive, computer-based targeted cognitive training in improving neurocognitive deficits in people with schizophrenia.


Options:
A: Arm Label: Physical activity; Type: EXPERIMENTAL; Interventions: Other: Physical activity | Arm Label: Computer game skills training; Type: ACTIVE_COMPARATOR; Interventions: Other: Computer game skills training | Intervention Type: OTHER; Name: Computer game skills training; Assigned to Arm(s): Computer game skills training | Intervention Type: OTHER; Name: Physical activity; Assigned to Arm(s): Physical activity
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Computer games | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Targeted cognitive training (TCT) | Intervention Type: BEHAVIORAL; Name: Targeted cognitive training (TCT); Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Computer games; Assigned to Arm(s): 1
C: Arm Label: Aerobic Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Aerobic Exercise | Arm Label: Standard Psychiatric Treatment; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard Psychiatric Treatment | Intervention Type: BEHAVIORAL; Name: Aerobic Exercise; Assigned to Arm(s): Aerobic Exercise | Intervention Type: OTHER; Name: Standard Psychiatric Treatment; Assigned to Arm(s): Standard Psychiatric Treatment
D: Arm Label: Targeted Cognitive Training; Type: EXPERIMENTAL; Interventions: Other: Targeted Cognitive Training | Arm Label: Social Cognitive Training; Type: EXPERIMENTAL; Interventions: Other: Social Cognitive Training | Intervention Type: OTHER; Name: Targeted Cognitive Training; Assigned to Arm(s): Targeted Cognitive Training | Intervention Type: OTHER; Name: Social Cognitive Training; Assigned to Arm(s): Social Cognitive Training

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Bosentan in Patients With Symptomatic Pulmonary Hypertension Associated With Sickle Cell Disease
Brief Summary: The study will assess the effect of bosentan on pulmonary vascular resistance and exercise capacity in Sickle Cell Disease (SCD) patients diagnosed with Pulmonary Hypertension. It consists of 3 phases: screening, treatment and follow-up. During the screening visit, the study doctor will decide if patients meet the study requirements. All potential patients will have a diagnosis of increased pulmonary artery pressures that is shown by right heart catheterization conducted shortly prior to start of study treatment. Patients will be asked to perform exercise capacity test (walking as far as possible for 6 minutes). Following the baseline visit the treatment phase consists of 4 additional clinic visits during which the good and bad effects of the drug are reviewed and exercise capacity test will be repeated. Patients will be treated for 16 weeks. Blood samples will be collected every month, or more often, if needed. At the end of the study some of the patients will be asked to repeat the right heart catheterization. All patients will repeat an exercise capacity test. After completion of the study, patients will have the option of enrolling in a long-term follow-up study where all patients will receive active drug. Patients electing not to participate in the extension study will be followed up for safety assessments for about 28 days after the end of the study treatment.


Options:
A: Arm Label: Bosentan; Type: EXPERIMENTAL; Interventions: Drug: Bosentan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Bosentan; Assigned to Arm(s): Bosentan | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Ambrisentan; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: bosentan | Intervention Type: DRUG; Name: bosentan; Assigned to Arm(s): 2
D: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: tadalafil | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: tadalafil | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: tadalafil | Arm Label: 5; Type: ACTIVE_COMPARATOR; Interventions: Drug: tadalafil | Intervention Type: DRUG; Name: tadalafil; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: tadalafil; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: tadalafil; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: tadalafil; Assigned to Arm(s): 5 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 1

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Bosentan in Patients With Symptomatic Pulmonary Hypertension Associated With Sickle Cell Disease
Brief Summary: The study will assess the effect of bosentan on pulmonary vascular resistance and exercise capacity in Sickle Cell Disease (SCD) patients diagnosed with Pulmonary Hypertension. It consists of 3 phases: screening, treatment and follow-up. During the screening visit, the study doctor will decide if patients meet the study requirements. All potential patients will have a diagnosis of increased pulmonary artery pressures that is shown by right heart catheterization conducted shortly prior to start of study treatment. Patients will be asked to perform exercise capacity test (walking as far as possible for 6 minutes). Following the baseline visit the treatment phase consists of 4 additional clinic visits during which the good and bad effects of the drug are reviewed and exercise capacity test will be repeated. Patients will be treated for 16 weeks. Blood samples will be collected every month, or more often, if needed. At the end of the study some of the patients will be asked to repeat the right heart catheterization. All patients will repeat an exercise capacity test. After completion of the study, patients will have the option of enrolling in a long-term follow-up study where all patients will receive active drug. Patients electing not to participate in the extension study will be followed up for safety assessments for about 28 days after the end of the study treatment.


Options:
A: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Bosentan | Intervention Type: DRUG; Name: Bosentan; Assigned to Arm(s): 2
B: Arm Label: Blood Transfusion Trial Cohort; Type: ACTIVE_COMPARATOR; Interventions: Biological: Single blood transfusion | Arm Label: Standard Care Trial Cohort; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard care | Arm Label: Standard Care Observational Cohort; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard care | Intervention Type: BIOLOGICAL; Name: Single blood transfusion; Assigned to Arm(s): Blood Transfusion Trial Cohort | Intervention Type: BEHAVIORAL; Name: Standard care; Assigned to Arm(s): Standard Care Observational Cohort, Standard Care Trial Cohort
C: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: bosentan | Intervention Type: DRUG; Name: bosentan; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: Bosentan; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Bosentan in Patients With Symptomatic Pulmonary Hypertension Associated With Sickle Cell Disease
Brief Summary: The study will assess the effect of bosentan on pulmonary vascular resistance and exercise capacity in Sickle Cell Disease (SCD) patients diagnosed with Pulmonary Hypertension. It consists of 3 phases: screening, treatment and follow-up. During the screening visit, the study doctor will decide if patients meet the study requirements. All potential patients will have a diagnosis of increased pulmonary artery pressures that is shown by right heart catheterization conducted shortly prior to start of study treatment. Patients will be asked to perform exercise capacity test (walking as far as possible for 6 minutes). Following the baseline visit the treatment phase consists of 4 additional clinic visits during which the good and bad effects of the drug are reviewed and exercise capacity test will be repeated. Patients will be treated for 16 weeks. Blood samples will be collected every month, or more often, if needed. At the end of the study some of the patients will be asked to repeat the right heart catheterization. All patients will repeat an exercise capacity test. After completion of the study, patients will have the option of enrolling in a long-term follow-up study where all patients will receive active drug. Patients electing not to participate in the extension study will be followed up for safety assessments for about 28 days after the end of the study treatment.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: bosentan | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: bosentan; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
B: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Bosentan | Intervention Type: DRUG; Name: Bosentan; Assigned to Arm(s): 2
C: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: bosentan | Intervention Type: DRUG; Name: bosentan; Assigned to Arm(s): 2
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: bosentan | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: bosentan; Assigned to Arm(s): A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): B

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Bosentan in Patients With Symptomatic Pulmonary Hypertension Associated With Sickle Cell Disease
Brief Summary: The study will assess the effect of bosentan on pulmonary vascular resistance and exercise capacity in Sickle Cell Disease (SCD) patients diagnosed with Pulmonary Hypertension. It consists of 3 phases: screening, treatment and follow-up. During the screening visit, the study doctor will decide if patients meet the study requirements. All potential patients will have a diagnosis of increased pulmonary artery pressures that is shown by right heart catheterization conducted shortly prior to start of study treatment. Patients will be asked to perform exercise capacity test (walking as far as possible for 6 minutes). Following the baseline visit the treatment phase consists of 4 additional clinic visits during which the good and bad effects of the drug are reviewed and exercise capacity test will be repeated. Patients will be treated for 16 weeks. Blood samples will be collected every month, or more often, if needed. At the end of the study some of the patients will be asked to repeat the right heart catheterization. All patients will repeat an exercise capacity test. After completion of the study, patients will have the option of enrolling in a long-term follow-up study where all patients will receive active drug. Patients electing not to participate in the extension study will be followed up for safety assessments for about 28 days after the end of the study treatment.


Options:
A: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Bosentan | Intervention Type: DRUG; Name: Bosentan; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: Bosentan; Assigned to Arm(s): N/A
C: Arm Label: Blood Transfusion Trial Cohort; Type: ACTIVE_COMPARATOR; Interventions: Biological: Single blood transfusion | Arm Label: Standard Care Trial Cohort; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard care | Arm Label: Standard Care Observational Cohort; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard care | Intervention Type: BIOLOGICAL; Name: Single blood transfusion; Assigned to Arm(s): Blood Transfusion Trial Cohort | Intervention Type: BEHAVIORAL; Name: Standard care; Assigned to Arm(s): Standard Care Observational Cohort, Standard Care Trial Cohort
D: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: bosentan | Intervention Type: DRUG; Name: bosentan; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Roflumilast in COPD Patients Treated With Salmeterol. A 24-week, Double-blind Study With 500 μg Roflumilast Once Daily Versus Placebo. The EOS Study
Brief Summary: The aim of the study is to compare the efficacy of roflumilast on pulmonary function and symptomatic parameters in patients with chronic obstructive pulmonary disease (COPD) during concomitant administration of salmeterol. The study duration will last up to 28 weeks. The study will provide further data on safety and tolerability of roflumilast.


Options:
A: Arm Label: Roflumilast; Type: ACTIVE_COMPARATOR; Interventions: Drug: Roflumilast | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): Roflumilast | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Daliresp; Type: ACTIVE_COMPARATOR; Interventions: Drug: roflumilast | Intervention Type: DRUG; Name: roflumilast; Assigned to Arm(s): Daliresp | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Roflumilast | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Roflumilast; Type: ACTIVE_COMPARATOR; Interventions: Drug: Roflumilast | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): Roflumilast | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Roflumilast in COPD Patients Treated With Salmeterol. A 24-week, Double-blind Study With 500 μg Roflumilast Once Daily Versus Placebo. The EOS Study
Brief Summary: The aim of the study is to compare the efficacy of roflumilast on pulmonary function and symptomatic parameters in patients with chronic obstructive pulmonary disease (COPD) during concomitant administration of salmeterol. The study duration will last up to 28 weeks. The study will provide further data on safety and tolerability of roflumilast.


Options:
A: Arm Label: Roflumilast; Type: ACTIVE_COMPARATOR; Interventions: Drug: Roflumilast | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): Roflumilast | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Roflumilast; Type: ACTIVE_COMPARATOR; Interventions: Drug: Roflumilast | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): Roflumilast | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): N/A
D: Arm Label: Roflumilast; Type: ACTIVE_COMPARATOR; Interventions: Drug: Roflumilast | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): Roflumilast | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A